[Human pharmacokinetics of AR-L 115 BS (author's transl)].
Following i.v. administration of 0.7 mg of 2-[(2-methoxy-4-methylsulfinyl)phenyl]-1H-imidazo[4,5-b]pyridine (AR-L 115 BS)/kg (bolus) the terminal plasma elimination half-life (beta-phase) was in the range of 50 min. A fast absorption of the patent compound could be observed after oral administration of 50, 75, 10 and 150 mg AR-L 115 BS (solution). The AR-L 115 BS plasma level behaviour was characterised by a fast elimination of the parent compound.